Adaptimmune Announces Changes to Board of Directors
April 12 2018 - 8:00AM
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell
therapy to treat cancer, today announced that, in a planned
transition, John Furey has been appointed as an independent
Non-Executive Director, and Peter Thompson, M.D., Ph.D., will be
stepping down from the Board. Both changes are effective from July
5, 2018. Mr. Furey will also succeed Dr. Thompson as a member of
the Remuneration Committee. Dr. Thompson has served as a
Non-Executive Director of Adaptimmune since September 2014.
“Peter’s deep oncology expertise and broad experience of
building companies has been invaluable as we moved towards being a
fully-integrated T-cell therapy company. On behalf of the Board and
management, I want to thank him for his support and contribution
over the past four years,” said James Noble, Adaptimmune’s Chief
Executive Officer. “As we move towards commercialization, John has
the optimal experience to assist us.”
“I am delighted to welcome John to the Board,” commented David
Mott, Adaptimmune’s Chairman. “His substantial experience and
strategic expertise across operational and commercial areas will be
particularly valuable as the Company progresses toward pivotal
trials, and plans to make the first treatment available to cancer
patients.”
John Furey said: “I am absolutely delighted to join Adaptimmune
at this exciting time. Its leadership position in the field of TCR
T-cell therapy offers great potential for cancer patients. I look
forward to working with the Board and the management team to
support advancement of the Company’s clinical programs, while
getting it ready for the next stages of commercialization.”
John Furey is Chief Operating Officer at Spark Therapeutics,
Inc. He is responsible for global commercial operations, medical
affairs, technology development and technical operations. He has 25
years of experience in developing and implementing operational
strategies and leading commercial and technical teams. Prior to
joining Spark Therapeutics, John was senior vice president and head
of global operations for Baxalta, where he directed manufacturing,
quality, engineering, and process development. He actively managed
a $2.5 billion production budget across Baxalta’s global network
and led a first-in-class supply chain organization for rare
diseases. John led the team that coordinated and delivered the
successful establishment of Baxalta through a spin out from Baxter
and led the Baxter Vaccine inline business to realize significant
top line and bottom line growth. He also spent two years in China
as general manager of Pfizer’s vaccine business unit following a
role with responsibility for global pricing and reimbursement at
Pfizer Vaccines. In these roles, John gained extensive experience
in pipeline development and global product launches. Earlier in his
career, he held both commercial and operations positions of
increasing scope and responsibility with Pfizer and Wyeth
Pharmaceuticals. John has an executive M.B.A. from St. Joseph’s
University, Philadelphia, a B.S. from Trinity College, Dublin, and
a diploma in Environmental Health from the Dublin Institute of
Technology.
About AdaptimmuneAdaptimmune is a
clinical-stage biopharmaceutical company focused on the development
of novel cancer immunotherapy products. The Company’s unique SPEAR
(Specific Peptide Enhanced Affinity Receptor) T‑cell platform
enables the engineering of T-cells to target and destroy cancer,
including solid tumors. Adaptimmune is currently conducting
clinical trials with SPEAR T-cells targeting MAGE-A4, -A10, and AFP
across several solid tumor indications. GlaxoSmithKline plc
(LSE:GSK) (NYSE:GSK) exercised its option to exclusively license
the right to research, develop, and commercialize Adaptimmune’s
NY-ESO SPEAR T-cell therapy program in September 2017. Transition
of this program to GSK is ongoing. The Company is located in
Philadelphia, USA and Oxfordshire, U.K. For more information,
please visit http://www.adaptimmune.com
Forward-Looking StatementsThis release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995 (PSLRA). These
forward-looking statements involve certain risks and uncertainties.
Such risks and uncertainties could cause our actual results to
differ materially from those indicated by such forward-looking
statements, and include, without limitation: the success, cost and
timing of our product development activities and clinical trials
and our ability to successfully advance our TCR therapeutic
candidates through the regulatory and commercialization processes.
For a further description of the risks and uncertainties that could
cause our actual results to differ materially from those expressed
in these forward-looking statements, as well as risks relating to
our business in general, we refer you to our Annual Report on Form
10-K filed with the Securities and Exchange Commission (SEC) on
March 15, 2018, and our other SEC filings. The forward-looking
statements contained in this press release speak only as of the
date the statements were made and we do not undertake any
obligation to update such forward‑looking statements to reflect
subsequent events or circumstances.
Adaptimmune Contacts:
Media Relations:Sébastien Desprez – VP, Communications and
Investor RelationsT: +44 1235 430 583M: +44 7718 453 176
Sebastien.Desprez@adaptimmune.com
Investor Relations: Juli P. Miller, Ph.D. – Director, Investor
RelationsT: +1 215 825 9310M: +1 215 460
8920Juli.Miller@adaptimmune.com
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Sep 2023 to Sep 2024